Everolimus in HR+ metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study May 14, 2019
BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with ER+ advanced or MBC, & in a PIK3CA mutant sub-population March 12, 2019